albumin-bound paclitaxel

P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

P2, N=90, Not yet recruiting, Tang-Du Hospital

P3, N=541, Active, not recruiting, DualityBio Inc. | Recruiting --> Active, not recruiting

P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2026 --> Feb 2027

This study evaluated a novel combination of DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable or metastatic melanoma (77.8% [21/27] previously treated with anti-PD-[L]1 and 22.2% [6/27] treatment-naïve mucosal melanoma; subtypes: 13 mucosal, 6 acral, 5 cutaneous, and 3 of unknown primary origin). Therefore, the combination of LAG-3/PD-1 blockade and chemotherapy demonstrated promising efficacy, notably in treatment-naïve mucosal melanoma with liver metastases. (Chinese Clinical Trial Registry number, ChiCTR2400079543).

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

This study reports AGP regimen as a promising therapeutic modality for PDAC, and provides a detailed mechanism by which a STING-mediated signaling relay from PDAC tumor cells to TAMs boost antitumor immunity and contribute to AGP chemotherapy efficacy. Furthermore, STING expression in tumor tissues correlated with improved prognosis, highlighting its potential as a predictive biomarker and promising therapeutic target.

P3, N=999, Recruiting, Akeso | Not yet recruiting --> Recruiting

P3, N=558, Not yet recruiting, Chipscreen Biosciences, Ltd.

P1/2, N=84, Not yet recruiting, Anova Innovation Limited

A total of 43 patients diagnosed with International Federation of Gynecology and Obstetrics 2018 stage IB3, IIA2, IIB, or IIIC1r will receive iparomlimab and tuvonralimab (5 mg/kg, intravenously), nab-paclitaxel (60 mg/m², intravenously), and cisplatin (75-80 mg/m², intravenously) for the first cycle. Additionally, the exploratory endpoint will focus on identifying predictive biomarkers associated with tumor response. ClinicalTrials.gov Identifier: NCT07055399.

The in vivo experiments validated the combination of PTX chemotherapy and DICG phototherapy elicited robust antitumor immunity, realizing a better tumor treatment compared to commercial Abraxane. This hypoxia-responsive nanoplatform exemplifies a promising strategy for enhancing treatment precision and efficacy against tumors.